Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.66 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918023 | 0.93 | TSHR (0.57) | CCR3MCHR1DRD4TSHRHRH3 | |
| SCHEMBL4923562 | 0.86 | TSHR (0.54) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4915835 | 0.85 | CCR3 (0.74) | CCR3MCHR1DRD4TSHRHRH3 | |
| SCHEMBL14198792 | 0.84 | HTR2A (0.53) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4914304 | 0.83 | TSHR (0.51) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4923547 | 0.82 | TSHR (0.50) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4921868 | 0.82 | PDE4A (0.49) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4924883 | 0.82 | TSHR (0.49) | CCR3MCHR1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL5577836 | 0.81 | TSHR (0.59) | CCR3MCHR1TSHRSMN1; SMN2 | |
| SCHEMBL4922766 | 0.81 | TSHR (0.49) | CCR3MCHR1DRD4TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | CCR3 2/4885MCHR1 358/4885DRD4 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.